EMEA suspends J&J's Ionsys on defects

1 December 2008

The European Medicines Agency (EMEA) has recommended the suspension of the marketing authorization of Johnson & Johnson's painkiller skin patch Ionsys (fentanyl HCl) because of a defect with the drug delivery system that could lead to overdosing.

The product was cleared in Europe in January 2006 and is indicated for the management in hospital of acute moderate-to-severe post-operative pain. The EMEA's Committee for Medicinal Products for Human Use (CHMP) was informed by J&J unit Janssen-Cilag that it had detected corrosion of a component of the drug-delivery system in a batch of Ionsys that could trigger self-activation. In September, J&J voluntarily withdrew the patch from the European market as a precaution. Patients have been switched to alternatives.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight